Study identifier:D5180C00032
ClinicalTrials.gov identifier:NCT05329194
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under-Studied Populations in the United States (PASSAGE)
asthma
Phase 4
No
Tezepelumab
All
285
Interventional
12 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Tezepelumab Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48. | - |